A recent pause in U.S. sales of Varipulse is hampering the company’s bid to catch up in one of the industry’s fastest-growing ...

Johnson & Johnson faces a critical test on Tuesday over its $10 billion proposal to end litigation alleging that its baby ...

in a move that will boost its share of the market for medical devices to treat heart disease. Under the terms of the deal, J&J will pay $335 a share in cash, equal to a 4.7% premium over Shockwave ...

Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States ...

Johnson & Johnson aims to streamline operations by selling its stroke care business, Cerenovus, valued at $1B+.

J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.

B Health and two safety-net hospitals want to help the government prove that drugmakers are required to give upfront discounts on 340B drugs.

Read about the spot won by J&J Worldwide Services on a U.S. Army multiple-award contract to provide repair, renovation and ...

weak medical device sales in China, and potential generic competition for its drug Stelara. Senior Health Reporter Anjalee Khemlani joins Market Domination to break down J&J's latest quarter.

"Darzalex continues to be a pillar brand with respect to performance," said J&J's Wolk in an interview, noting that sales from Shockwave Medical also helped drive growth.

Under the contract, J&J will help meet medical facility requirements across the continental U.S., Hawaii, Alaska, the District of Columbia, Guam and Puerto Rico. The Department of Defense said ...